King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification
This article was originally published in The Pink Sheet Daily
Executive Summary
With the Skelaxin story "over," King is pushing ahead with plans to resubmit abuse-deterrent opioids Remoxy and Acurox for FDA approval and fine-tuning its sales force to improve performance of Embeda.
You may also be interested in...
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise
Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
Pfizer To Buy King Pharma For $3.6 billion In Order to Strengthen Pain Franchise
Pfizer will gain access to King's specialized portfolio of medications for acute, severe pain and to Remoxy, which could catapult the Big Pharma into the controversial but promising field of tamper-resistant opioid medications.